203 related articles for article (PubMed ID: 20173407)
1. Vaccines against malaria: perspectives from Papua New Guinea.
Mueller I; Genton B; Betuela I; Alpers MP
Hum Vaccin; 2010 Jan; 6(1):17-20. PubMed ID: 20173407
[TBL] [Abstract][Full Text] [Related]
2. Malaria vaccine clinical trials: what's on the horizon.
Moreno A; Joyner C
Curr Opin Immunol; 2015 Aug; 35():98-106. PubMed ID: 26172291
[TBL] [Abstract][Full Text] [Related]
3. Plasmodium vivax malaria vaccines: why are we where we are?
Reyes-Sandoval A; Bachmann MF
Hum Vaccin Immunother; 2013 Dec; 9(12):2558-65. PubMed ID: 23978931
[TBL] [Abstract][Full Text] [Related]
4. Higher Complexity of Infection and Genetic Diversity of
Fola AA; Harrison GLA; Hazairin MH; Barnadas C; Hetzel MW; Iga J; Siba PM; Mueller I; Barry AE
Am J Trop Med Hyg; 2017 Mar; 96(3):630-641. PubMed ID: 28070005
[No Abstract] [Full Text] [Related]
5. MALVAC 2012 scientific forum: accelerating development of second-generation malaria vaccines.
Vannice KS; Brown GV; Akanmori BD; Moorthy VS
Malar J; 2012 Nov; 11():372. PubMed ID: 23140365
[TBL] [Abstract][Full Text] [Related]
6. Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation.
Tachibana M; Takashima E; Morita M; Sattabongkot J; Ishino T; Culleton R; Torii M; Tsuboi T
Parasitol Int; 2022 Apr; 87():102525. PubMed ID: 34896614
[TBL] [Abstract][Full Text] [Related]
7. Malaria Vaccines: Recent Advances and New Horizons.
Draper SJ; Sack BK; King CR; Nielsen CM; Rayner JC; Higgins MK; Long CA; Seder RA
Cell Host Microbe; 2018 Jul; 24(1):43-56. PubMed ID: 30001524
[TBL] [Abstract][Full Text] [Related]
8. Overview: immunology of malaria and progress in malaria vaccine development.
Tharavanij S
Southeast Asian J Trop Med Public Health; 1992 Sep; 23 Suppl 4():71-87. PubMed ID: 1364871
[No Abstract] [Full Text] [Related]
9. Vaccines against Plasmodium vivax: a research challenge.
Patarroyo MA; Calderón D; Moreno-Pérez DA
Expert Rev Vaccines; 2012 Oct; 11(10):1249-60. PubMed ID: 23176656
[TBL] [Abstract][Full Text] [Related]
10. Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children.
Lin E; Kiniboro B; Gray L; Dobbie S; Robinson L; Laumaea A; Schöpflin S; Stanisic D; Betuela I; Blood-Zikursh M; Siba P; Felger I; Schofield L; Zimmerman P; Mueller I
PLoS One; 2010 Feb; 5(2):e9047. PubMed ID: 20140220
[TBL] [Abstract][Full Text] [Related]
11. Low efficacy of amodiaquine or chloroquine plus sulfadoxine-pyrimethamine against Plasmodium falciparum and P. vivax malaria in Papua New Guinea.
Marfurt J; Müeller I; Sie A; Maku P; Goroti M; Reeder JC; Beck HP; Genton B
Am J Trop Med Hyg; 2007 Nov; 77(5):947-54. PubMed ID: 17984359
[TBL] [Abstract][Full Text] [Related]
12. The risk of malarial infections and disease in Papua New Guinean children.
Michon P; Cole-Tobian JL; Dabod E; Schoepflin S; Igu J; Susapu M; Tarongka N; Zimmerman PA; Reeder JC; Beeson JG; Schofield L; King CL; Mueller I
Am J Trop Med Hyg; 2007 Jun; 76(6):997-1008. PubMed ID: 17556601
[TBL] [Abstract][Full Text] [Related]
13. Current status of Plasmodium vivax vaccine.
Arévalo-Herrera M; Chitnis C; Herrera S
Hum Vaccin; 2010 Jan; 6(1):124-32. PubMed ID: 20009526
[TBL] [Abstract][Full Text] [Related]
14. Plasmodium vivax VIR Proteins Are Targets of Naturally-Acquired Antibody and T Cell Immune Responses to Malaria in Pregnant Women.
Requena P; Rui E; Padilla N; Martínez-Espinosa FE; Castellanos ME; Bôtto-Menezes C; Malheiro A; Arévalo-Herrera M; Kochar S; Kochar SK; Kochar DK; Umbers AJ; Ome-Kaius M; Wangnapi R; Hans D; Menegon M; Mateo F; Sanz S; Desai M; Mayor A; Chitnis CC; Bardají A; Mueller I; Rogerson S; Severini C; Fernández-Becerra C; Menéndez C; Del Portillo H; Dobaño C
PLoS Negl Trop Dis; 2016 Oct; 10(10):e0005009. PubMed ID: 27711158
[TBL] [Abstract][Full Text] [Related]
15. Research challenges and gaps in malaria knowledge in Papua New Guinea.
Kazura JW; Siba PM; Betuela I; Mueller I
Acta Trop; 2012 Mar; 121(3):274-80. PubMed ID: 21896268
[TBL] [Abstract][Full Text] [Related]
16. Significant geographical differences in prevalence of mutations associated with Plasmodium falciparum and Plasmodium vivax drug resistance in two regions from Papua New Guinea.
Barnadas C; Timinao L; Javati S; Iga J; Malau E; Koepfli C; Robinson LJ; Senn N; Kiniboro B; Rare L; Reeder JC; Siba PM; Zimmerman PA; Karunajeewa H; Davis TM; Mueller I
Malar J; 2015 Oct; 14():399. PubMed ID: 26452541
[TBL] [Abstract][Full Text] [Related]
17. Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses.
White M; Amino R; Mueller I
Trends Parasitol; 2017 Apr; 33(4):260-263. PubMed ID: 28077251
[TBL] [Abstract][Full Text] [Related]
18. The use of transgenic parasites in malaria vaccine research.
Othman AS; Marin-Mogollon C; Salman AM; Franke-Fayard BM; Janse CJ; Khan SM
Expert Rev Vaccines; 2017 Jul; 16(7):1-13. PubMed ID: 28525963
[TBL] [Abstract][Full Text] [Related]
19. Guidance on the evaluation of Plasmodium vivax vaccines in populations exposed to natural infection.
Mueller I; Moorthy VS; Brown GV; Smith PG; Alonso P; Genton B;
Vaccine; 2009 Sep; 27(41):5633-43. PubMed ID: 19638270
[TBL] [Abstract][Full Text] [Related]
20. Knowledge, attitudes, and practices concerning malaria in pregnancy: results from a qualitative study in Madang, Papua New Guinea.
Andrew EV; Pell C; Angwin A; Auwun A; Daniels J; Mueller I; Phuanukoonnon S; Pool R
PLoS One; 2015; 10(4):e0119077. PubMed ID: 25893405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
